1. Research Infrastructures
  2. TrGET, preclinical platform in oncology

TrGET, preclinical platform in oncology

CONTACT
Coordinates 43.29236346203756, 5.359133426541125
Contact name Yves Collette
CIVIS Label No
Acronym TrGET-PTA
Scientific domain

LS4_12 - Cancer - Physiology in Health, Disease and Ageing


 

LS4_3 - Physiology of ageing - Physiology in Health, Disease and Ageing


Keywords

Oncology


 

drug sensitivity/resistance profiling


 

drug testing


 

animal models


 

preclinicals


Partner institution

Aix-Marseille Université


Website No
Technical staff available No
Remote access details The TrGET platform is open to the scientific community from both the academia and private sectors. Those wishing to use the platform must submit their request in the form of a project to the scientific and technical TrGET managers; the project should include a description of the experiments to be carried out, the expected involvement of the RI staff, and a first draft of provisional specifications. The request acceptance depends on the project feasibility, its adequacy with the platform services and access schedule and, to a certain extent, the strategic priorities of the RI team.
Remote access available No
Open to external users No
Equipment TrGET evaluates in vitro and in vivo gene candidates involved in tumorogenesis as well as efficacy of novel and/or combined therapies in oncology for both fundamental and translational research. A variety of flexible and customisable services are available, using last advanced bioluminescence technologies and so quantitative evaluation of cell characteristics in vitro (e.g., viability, proliferation, apoptosis, clonogenicity, migration), as well as in vivo (tumour progression and aggressiveness, metastatic development). In vitro, the optimisation of therapeutic strategies is also made possible thanks to the synergistic effects from various chemotherapy molecules or other type of therapies (e.g., COMBO-SCREEN programme). In vivo, original and innovative models of xenografts are made available and/or co-developed from established cell lines and primary bioluminescent samples (e.g., Drug Sensitivity & Resistance Profiling plateform); the latter guarantees an evaluation in respect to ethical considerations related to animal experimentation. In addition, TrGET can also be called upon to provide accommodation/training/supervision for staff coming to carry out experiments. TrGET works directly with the CRCM and IPC platforms - other Aix-Marseille University platforms notably specialized in cytometry, proteomics, IPC-Drug discovery, as well as research and clinical departments, including the Biobank and the human Early Clinical Trial Center.
Open access to updated information database No
Online booking system details Charte des Plateformes Technologiques Aix-Marseille (PTA): https://www.univ-amu.fr/system/files/2021-07/Charte%20PTF%20AMU%20M%C3%A0J21.docx.pdf
Online booking system available No
Description The TrGET preclinical platform, hosted by the Centre de Recherche en Cancérologie de Marseille (CRCM), an Inserm-CNRS-University research unit dedicated to cancer research and development, is located on the site of the Institut Paoli- Calmettes, the regional cancer centre of Marseille. TrGET offers services for the evaluation, the validation and the optimisation of therapeutic strategies in oncology, in vitro (cell tests) and in vivo (cell line and patient-derived xenograft models).